^
Association details:
| Biomarker: | EGFR exon 19 deletion + MET Amplification + MET D1228V |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Tagrisso (osimertinib) (EGFR inhibitor) + Orpathys (savolitinib) (c-MET inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer
Excerpt:
...we present a case of a patient with lung adenocarcinoma harboring both a mutation in EGFR and an amplification of MET, who after progression on erlotinib responded dramatically to combined MET and EGFR inhibition with savolitinib and osimertinib...When resistance developed to this combination, a new MET kinase domain mutation, D1228V, was detected.
DOI:
10.1158/2159-8290.CD-16-0686
